Efficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortality

Basit Öğe Kaydı
dc.authoridKasapoglu, Umut Sabri/0000-0003-2869-9872
dc.authoridtetik, bora/0000-0001-7696-7785
dc.authoridAcun Delen, Leman/0000-0001-9441-6979
dc.authorwosidKasapoglu, Umut Sabri/F-1786-2019
dc.authorwosidtetik, bora/AAA-8841-2021
dc.contributor.authorDelen, Leman
dc.contributor.authorKasapoglu, Umut Sabri
dc.contributor.authorGok, Abdullah
dc.contributor.authorCagasar, Ozlem
dc.contributor.authorTetik, Bora
dc.contributor.authorOksuz, Ersoy
dc.date.accessioned2024-08-04T20:53:07Z
dc.date.available2024-08-04T20:53:07Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: In coronavirus disease - 19 (COVID-19) patients, cytokine storm develops due to the increase of pro-inflammatory cytokines. Tocilizumab (TU.), has been used in the treatment of COVID-19 patients and successful results have been obtained. The aim of this study was to determine the efficacy of TCZ and also investigate the prognostic factors affecting the success of treatment and mortality in COVID-19 patients treated with TCZ. Patients and Methods: Between March 2020 and August 2021, a total of 326 confirmed severe COVID-19 pneumonia patients, treated in the intensive care unit, were included in the study. Results: The mean age of the patients was 63.02 +/- 11.58 years, and 203 (62.3%) of the patients were male. Patients treated with TCZ had a longer survival time compared with the standard therapy (p=0.012). It was found that type of respiratory support (HR:2.19, CI:1.10-4.36, p=0.025) and hyperlactatemia on the day of TCZ therapy admission (HR:2.93 CI:1.53-5.64, p=0.001) were the significant and independent prognostic factors of survival in severe COVID-19 pneumonia patients treated with TCZ. Conclusion: Tocilizumab therapy improved 30-days survival in critically ill COVID-19 pneumonia patients. Also, among the patients with TCZ, types of respiratory support and hyperlactatemia on the day of TCZ admission were the independent prognostic factors.en_US
dc.identifier.doi10.5472/marumj.1191126
dc.identifier.endpage315en_US
dc.identifier.issn1309-9469
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85141399359en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage308en_US
dc.identifier.urihttps://doi.org/10.5472/marumj.1191126
dc.identifier.urihttps://hdl.handle.net/11616/100982
dc.identifier.volume35en_US
dc.identifier.wosWOS:000878860500007en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMarmara Univ, Fac Medicineen_US
dc.relation.ispartofMarmara Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSARS-CoV-2en_US
dc.subjectCOVID-19en_US
dc.subjectTocilizumaben_US
dc.subjectViral pneumoniaen_US
dc.subjectCytokine stormen_US
dc.subjectPrognostic factorsen_US
dc.titleEfficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortalityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu